89 related articles for article (PubMed ID: 29948864)
1. The use of anti-ulcer agents and the risk of chronic kidney disease: a meta-analysis.
Sun J; Sun H; Cui M; Sun Z; Li W; Wei J; Zhou S
Int Urol Nephrol; 2018 Oct; 50(10):1835-1843. PubMed ID: 29948864
[TBL] [Abstract][Full Text] [Related]
2. Non-indicated initiation of proton pump inhibitor and risk of adverse outcomes in patients with underlying chronic kidney disease: a nationwide, retrospective, cohort study.
Kim SG; Cho JM; Han K; Joo KW; Lee S; Kim Y; Cho S; Huh H; Kim M; Kang E; Kim DK; Park S
BMJ Open; 2024 Jan; 14(1):e078032. PubMed ID: 38286693
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors and chronic kidney disease risk: a comparative study with histamine-2 receptor antagonists.
Kweon T; Kim Y; Lee KJ; Seo WW; Seo SI; Shin WG; Shin DH
Sci Rep; 2023 Dec; 13(1):21169. PubMed ID: 38036592
[TBL] [Abstract][Full Text] [Related]
4. Duration and dosing of Proton Pump Inhibitors associated with high incidence of chronic kidney disease in population-based cohort.
Rodríguez-Poncelas A; Barceló MA; Saez M; Coll-de-Tuero G
PLoS One; 2018; 13(10):e0204231. PubMed ID: 30332411
[TBL] [Abstract][Full Text] [Related]
5. Blood Pressure Variability and the Progression of Chronic Kidney Disease: a Systematic Review and Meta-Analysis.
Yang L; Li J; Wei W; Pu Y; Zhang L; Cui T; Ma L; Wang B; Zhao Y; Fu P
J Gen Intern Med; 2023 Apr; 38(5):1272-1281. PubMed ID: 36650323
[TBL] [Abstract][Full Text] [Related]
6. Changes in estimated glomerular filtration rate in patients administered proton pump inhibitors: a single-center cohort study.
Murofushi T; Yagi T; Tsuji D; Furushima D; Fujikura T; Itoh K; Kawakami J
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; ():. PubMed ID: 38170305
[TBL] [Abstract][Full Text] [Related]
7. Acid-suppressive drugs and risk of kidney disease: A systematic review and meta-analysis.
Qiu T; Zhou J; Zhang C
J Gastroenterol Hepatol; 2018 Apr; ():. PubMed ID: 29644725
[TBL] [Abstract][Full Text] [Related]
8. Association of cadmium environmental exposure with chronic kidney disease: A systematic review and meta-analysis.
Doccioli C; Sera F; Francavilla A; Cupisti A; Biggeri A
Sci Total Environ; 2024 Jan; 906():167165. PubMed ID: 37758140
[TBL] [Abstract][Full Text] [Related]
9. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
Moayyedi P; Eikelboom JW; Bosch J; Connolly SJ; Dyal L; Shestakovska O; Leong D; Anand SS; Störk S; Branch KRH; Bhatt DL; Verhamme PB; O'Donnell M; Maggioni AP; Lonn EM; Piegas LS; Ertl G; Keltai M; Bruns NC; Muehlhofer E; Dagenais GR; Kim JH; Hori M; Steg PG; Hart RG; Diaz R; Alings M; Widimsky P; Avezum A; Probstfield J; Zhu J; Liang Y; Lopez-Jaramillo P; Kakkar AK; Parkhomenko AN; Ryden L; Pogosova N; Dans AL; Lanas F; Commerford PJ; Torp-Pedersen C; Guzik TJ; Vinereanu D; Tonkin AM; Lewis BS; Felix C; Yusoff K; Metsarinne KP; Fox KAA; Yusuf S;
Gastroenterology; 2019 Sep; 157(3):682-691.e2. PubMed ID: 31152740
[TBL] [Abstract][Full Text] [Related]
10. The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma.
Mense ES; Smit AAJ; Crul M; Franssen EJF
J Clin Pharm Ther; 2019 Apr; 44(2):249-257. PubMed ID: 30578577
[TBL] [Abstract][Full Text] [Related]
11. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.
Hart E; Dunn TE; Feuerstein S; Jacobs DM
Pharmacotherapy; 2019 Apr; 39(4):443-453. PubMed ID: 30779194
[TBL] [Abstract][Full Text] [Related]
12. Do proton pump inhibitors increase mortality? A systematic review and in-depth analysis of the evidence.
Ben-Eltriki M; Green CJ; Maclure M; Musini V; Bassett KL; Wright JM
Pharmacol Res Perspect; 2020 Oct; 8(5):e00651. PubMed ID: 32996701
[TBL] [Abstract][Full Text] [Related]
13. Association between a low dose of proton pump inhibitors and kidney function decline in elderly hypertensive patients: a retrospective observational study.
Wakabayashi T; Hosohata K; Oyama S; Inada A; Niinomi I; Kambara H; Iida T; Hasebe K; Matsuoka H; Uchida M; Kumagai E
J Int Med Res; 2021 Apr; 49(4):3000605211006653. PubMed ID: 33845606
[TBL] [Abstract][Full Text] [Related]
14. Omeprazole use and risk of chronic kidney disease evolution.
Guedes JVM; Aquino JA; Castro TLB; Augusto de Morais F; Baldoni AO; Belo VS; Otoni A
PLoS One; 2020; 15(3):e0229344. PubMed ID: 32130255
[TBL] [Abstract][Full Text] [Related]
15. Proton Pump Inhibitors and the Kidney: Implications of Current Evidence for Clinical Practice and When and How to Deprescribe.
Al-Aly Z; Maddukuri G; Xie Y
Am J Kidney Dis; 2020 Apr; 75(4):497-507. PubMed ID: 31606235
[TBL] [Abstract][Full Text] [Related]
16. Kidney function decline associated with proton pump inhibitors: results from the ELSA-Brasil cohort.
Dos Santos AS; de Menezes ST; Silva IR; Oliveira WN; Pereira ML; Mill JG; Barreto SM; Figueiredo RC
BMC Nephrol; 2023 Sep; 24(1):285. PubMed ID: 37770872
[TBL] [Abstract][Full Text] [Related]
17. Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies.
Wu CC; Liao MH; Kung WM; Wang YC
J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983271
[TBL] [Abstract][Full Text] [Related]
18. Risk of bias in non-randomized observational studies assessing the relationship between proton-pump inhibitors and adverse kidney outcomes: a systematic review.
Rajan P; Iglay K; Rhodes T; Girman CJ; Bennett D; Kalantar-Zadeh K
Therap Adv Gastroenterol; 2022; 15():17562848221074183. PubMed ID: 35173802
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
